日本真实世界数据揭示子宫内膜异位症流行病学特征
基于日本健康保险数据库2005年1月至2023年7月的描述性分析,纳入15岁及以上、随访至少2年的女性,共识别285,309例子宫内膜异位症患者(15-50岁诊断)。2022年患病率达3.62%,发病高峰在26岁;至50岁的假设累积发病率整体为37.34%,需药物治疗者为20.08%。
要点
- 2022年日本女性子宫内膜异位症患病率为3.62%,2006至2022年持续上升。
- 发病高峰年龄为26岁;高龄组子宫腺肌病发病率高于子宫内膜异位囊肿。
- 至50岁假设累积发病率整体37.34%,需药物治疗者20.08%。
核心结论
- 至50岁的假设终生发病率约为女性的三分之一,其中五分之一需要药物治疗,提示需加强临床意识与管理。
研究设计与样本
- 基于日本健康保险数据库2005年1月至2023年7月的描述性分析,纳入15岁及以上、有至少2年随访数据的女性。
- 初始识别4,917,037名潜在参与者,其中285,309例在15-50岁诊断为子宫内膜异位症。
主要发现
- 2006至2022年患病率持续上升,2022年达3.62%。
- 发病高峰年龄为26岁;高龄组子宫腺肌病发病率高于子宫内膜异位囊肿。
- 假设累积发病率整体为37.34%,需药物治疗者为20.08%,两者均呈上升趋势。
临床怎么用
- 临床中应关注子宫内膜异位症在育龄女性中的高累积风险,尤其26岁左右发病高峰。
- 对高龄患者需注意鉴别子宫腺肌病与子宫内膜异位囊肿,前者发病率更高。
- 约五分之一女性至50岁需药物治疗,提示需优化长期管理策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Considering the progressively delayed age of pregnancy, what is the current epidemiology of endometriosis in Japan, including its prevalence, incidence and medication patterns, as revealed by a large-scale, real-world dataset? DESIGN: A descriptive analysis of a health insurance dataset from January 2005 to July 2023. The study included adolescent girls and women aged 15 years or older with available data and at least 2 years of follow-up data. The main outcome measures were the prevalence of endometriosis, the age-specific incidence and the hypothetical cumulative incidences. RESULTS: Initially, 4,917,037 adolescent girls and women with at least 2 years of follow-up data were identified as potential participants, 285,309 of whom were diagnosed with endometriosis at 15-50 years of age. The prevalence of endometriosis increased consistently from 2006 to 2022, reaching 3.62% in 2022. The highest incidence was observed at 26 years of age. In older groups, the incidence of adenomyosis was higher than that of endometrioma. The hypothetical cumulative incidences were 37.34% for overall endometriosis and 20.08% for endometriosis treated with medications, with increasing trends observed for both conditions. CONCLUSIONS: The hypothetical lifetime incidence of endometriosis by age 50 years was approximately one-third among women, and one-fifth required medication for its treatment, highlighting the need for increased awareness and improved management in clinical settings.
引用
- Ohashi M, Matsubayashi J, Sugeta K, et al. Epidemiology of endometriosis based on real-world data in Japan. Reprod Biomed Online. 2025. PMID: 41692664. doi:10.1016/j.rbmo.2025.105379
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。